Consensus on updated dosing recommendations for Y-90 Glass in HCC
Key updates from an international multidisciplinary working group include dosing recommendations below. These updates were driven by TheraSphere landmark studies and advancing Y-90 techniques to improve outcomes. See full publication or view the easy-to-navigate dosing recommendations resource.
- Five clinical scenarios (curative and palliative intent) to facilitate standardized personalized treatment to improve outcomes
- Targeted absorbed dose in selective treatment of ≥ 400 Gy for complete pathologic necrosis (radiation segmentectomy and modified radiation lobectomy)
- Tumor absorbed dose of ≥ 205 Gy (> 250 Gy where possible) and normal absorbed dose in the perfused liver of ≤ 120 Gy in patients with ≥ 30% hepatic reserve